Formulary exclusions for insulin aspart
Top formularies like Optum Rx and Express Scripts have excluded aspart as a class, potentially limiting TAM for Kirsty.
medium · analyst_questionBiocon Limited — Q2 FY26
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generics (+24% Y...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Competitive pricing pressure in biosimilars
Market share and ASPs are inversely proportional; increased competition could erode pricing and margins.
medium · management_commentaryDenosumab market crowded with five players
Five players are already in the Denosumab market with five more in the pipeline, increasing competitive intensity.
high · management_commentaryGenerics margin pressure from new facilities
Fixed costs from three new facilities capitalized in FY25 continue to pressure generics margins.
medium · data_observation